| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
See Remarks
1 company
Kathleen S. Capps is See Remarks at ENTA. Kathleen S. Capps's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $87K at current prices.
The ENTA filings lean toward selling, a net 530 shares.
Kathleen S. Capps has 3 Form 4 filings on record from November 2025 to December 2025, all as Enanta Pharmaceuticals (ENTA), 2025.
The 5 reported transactions were 2 open-market sales, 1 tax withholding, 1 stock award and 1 option or other derivative award.
Counted by filing, the open-market trades come to no purchases and 2 sales worth about $7K.
The largest open-market sale was 323 shares of ENTA at an average $14.23 on December 5, 2025, about $5K.
Neither of the two sales since April 2023 was marked as made under a Rule 10b5-1 trading plan.